2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Solid Tumor
1
Interventions
pembrolizumab
1034
Carboplatin
973
Paclitaxel
942
Gemcitabine
799
Cisplatin
759
Docetaxel
699
Bevacizumab
637
Nivolumab
520
Pemetrexed
509
Cyclophosphamide
476
Capecitabine
475
Fluorouracil
425
Dexamethasone
410
Rituximab
392
Oxaliplatin
352
Injections
349
Trastuzumab
314
atezolizumab
312
Cetuximab
291
Leucovorin
290
Irinotecan
271
130-nm albumin-bound paclitaxel
257
Prednisone
252
Ipilimumab
244
Doxorubicin
242
Lenalidomide
231
Fulvestrant
226
fludarabine
221
durvalumab
211
Erlotinib Hydrochloride
196
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
MK-4166
×
Clear all
NCT02132754
2021-01-28
MK-4166-001
Merck Sharp & Dohme LLC
Phase 1
Completed
116 enrolled
61 charts